Patient selection for complex, high-risk indicated percutaneous coronary intervention procedures: an overview.

Eur Heart J Suppl · 2026 · PMC13294556 · PMID 42368218

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Even though the primary endpoint (30-day MACE) was not statistically different between the groups in the intention-to-treat analysis (ITT), there was a strong trend in favour of the Impella 2.5 group at 90 days (Impella 2.5 40.6% vs.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.